Men with prostate cancer are often at risk for other age-related adverse events, such as hip fractures. Osteoporosis is a common consequence of androgen deprivation therapy (ADT) for prostate cancer. Up to 20% of men treated with ADT suffer fractures within 5 years [1][2][3]. It was previously believed that decreased sex hormone levels would induce the receptor activator of nuclear factor-kappa-B ligand in osteoblasts which consequently induced osteoclasts activate bone resorption [4]. We retrospectively investigated the risk of fracture in prostate cancer patients treated with ADT. The institutional review board of Yokohama City University approved this study.
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Takashi Kawahara Departments of Urology and Renal Transplantation, Yokohama City Medical Center, Yokohama, Japan tients, the incidence of bone fracture was higher (10/59, 16.9%) compared with the non-CRPC ADT group, and all fractures occurred in the metastatic bone. Pyramidal compression fracture was the major fracture spot (22/59, 45.8%) in the ADT group and (7/10, 70.0%) in CRPC patients. A previous report showed that patients with morbid fractures had a 40-month shorter overall survival [5] . However, there were no differences in the cancer specific survival and overall survival of CRPC patients between Takashi Kawahara and Shusei Fusayasu contributed equally to this work. 
